Combination paclitaxel (Taxol®)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer Conference Paper
| Authors: | Hoskins, W. J.; McGuire, W. P.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. |
| Title: | Combination paclitaxel (Taxol®)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer |
| Conference Title: | Current Concepts in the Management of Ovarian Cancer |
| Abstract: | The Gynecologic Oncology Group initiated a study to evaluate combination paclitaxel (Taxol®, Bristol-Myers Squibb Company)-cisplatin vs standard therapy with cyclophosphamide-cisplatin as primary therapy for patients with suboptinally debulked advanced ovarian cancer. The 386 eligible patients were randomly assigned to treatment with either cisplatin 75 mg m-2 plus cyclophosphamide 750 mg m-2 or the same dose of cisplatin plus paclitaxel 135 mg m-2 given over 24 h. Response to therapy was assessed in 216 patients with clinically measurable disease. In the standard therapy arm, overall response was 60%, with a 31% rate of complete response. In the paclitaxel-based treatment group, the overall response was 73%, and 51% of patients achieved a complete response. Although neutropenia, fever, alopecia, and peripheral neuropathy were more common in the paclitaxel-treated patients, myelosuppression was generally brief and nonhematologic toxicities were mild. Both overall and progression-free survival significantly favored patients treated with paclitaxel-cisplatin: overall survival was 37.5 vs 24.4 months, and progression-free survival was 17.9 vs 12.9 months for the paclitaxel- and cyclophosphamide-treated groups, respectively. Paclitaxel- cisplatin offers prolonged survival and progression-free survival without increasing toxicity when used as first-line therapy for patients with suboptimally debulked ovarian cancer. |
| Keywords: | adult; cancer survival; controlled study; aged; major clinical study; clinical trial; neutropenia; cisplatin; advanced cancer; cancer combination chemotherapy; dose response; conference paper; paclitaxel; ovarian cancer; controlled clinical trial; anemia; bone marrow suppression; gastrointestinal symptom; randomized controlled trial; peripheral neuropathy; cyclophosphamide; fever; ovary carcinoma; phase 3 clinical trial; alopecia; allergic reaction; human; female; priority journal; paclitaxel-cisplatin; paclitaxel-cyclophosphamide |
| Journal Title | International Journal of Gynecological Cancer |
| Volume: | 7 |
| Issue: | Suppl. 1 |
| Conference Dates: | 1996 Jun 14 |
| Conference Location: | Lyon, France |
| ISBN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 1997-05-01 |
| Start Page: | 9 |
| End Page: | 13 |
| Language: | English |
| DOI: | 10.1046/j.1525-1438.7.s1.5.x |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 17 March 2017 -- Source: Scopus |
